विजयपीडी स्युटिकल IPO वाटप स्थिती कशी तपासावी?

Vijaypd Ceutical Limited is engaged in distribution of pharmaceutical products and consumer goods offering comprehensive range of services, incorporated in October 1971, acting as representatives, dealers, agents, stockists, suppliers, traders, and packers serving pharmaceutical and wellness industries as well as FMCG market, offering products including medicines in various forms such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, liquid oral products, vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items including soaps, sanitizers, baby care products, ayurvedic products, cosmetics, food products, dental products, and crude drugs, serving over 2,109 pharmacies, clinics, and nursing homes across four districts covering 20 locations as of March 31, 2025, maintaining distribution network connecting with over 170 healthcare product manufacturers providing access to more than 19,000 SKUs, holding FDA, FSSAI, and BMC certifications with streamlined supply chain management and experienced management team.

The Vijaypd Ceutical IPO came with a total issue size of ₹19.25 crore, comprising entirely a fresh issue of 0.55 crore shares aggregating to ₹19.25 crore. The IPO opened on September 29, 2025, and closed on October 1, 2025. The allotment for the Vijaypd Ceutical IPO is expected to be finalized on Friday, October 3, 2025. The Vijaypd Ceutical IPO share price was fixed at ₹35 per share.

पुढील मोठा IPO चुकवू नका - केवळ काही क्लिकसह इन्व्हेस्ट करा!

आत्ताच अकाउंट उघडा

रजिस्ट्रार साईटवर विजयपीडी स्युटिकल IPO वाटप स्थिती तपासण्याच्या स्टेप्स

• भेट द्या केफिन टेक्नॉलॉजीज लि. वेबसाईट
• वाटप स्थिती पेजवर ड्रॉपडाउन मेन्यूमधून "विजयपीडी स्युटिकल" निवडा
• नियुक्त क्षेत्रात तुमचा PAN ID, डिमॅट अकाउंट नंबर किंवा ॲप्लिकेशन नंबर प्रविष्ट करा
• कॅप्चा पडताळणी प्रक्रिया पूर्ण करा आणि तुमची वाटप स्थिती पाहण्यासाठी "सबमिट करा" बटनावर क्लिक करा

NSE वर विजयपीडी स्युटिकल IPO वाटप स्थिती तपासण्याच्या स्टेप्स

• NSE SME IPO वाटप स्थिती पेज वर नेव्हिगेट करा
• समस्या प्रकार निवडा: इक्विटी/डेब्ट
• ड्रॉपडाउन मेन्यूमध्ये ॲक्टिव्ह IPO च्या यादीमधून "विजयपीडी स्युटिकल" निवडा
• आवश्यक क्षेत्रांमध्ये तुमचा ॲप्लिकेशन नंबर आणि PAN ID प्रविष्ट करा
• कॅप्चा पडताळा आणि तुमची वाटप स्थिती तपासण्यासाठी "शोधा" वर क्लिक करा

विजयपीडी स्युटिकल IPO सबस्क्रिप्शन स्थिती

Vijaypd Ceutical IPO received weak investor interest, being subscribed 1.37 times overall. या सबस्क्रिप्शनने कमकुवत रिटेल सहभाग आणि कमी NII व्याजासह कमी आत्मविश्वास दाखवला. ऑक्टोबर 1, 2025 रोजी 5:14:16 PM पर्यंत सबस्क्रिप्शनचे कॅटेगरी-निहाय ब्रेकडाउन येथे दिले आहे:

• नॉन-इन्स्टिट्यूशनल इन्व्हेस्टर (एनआयआय): 1.86 वेळा.
• रिटेल इन्व्हेस्टर: 0.89 वेळा.

Vijaypd Ceutical IPO Share Price and Investment Details

The Vijaypd Ceutical IPO stock price was fixed at ₹35 per share with a minimum lot size of 4,000 shares. The minimum investment required for retail investors was ₹2,80,000 for 2 lots (8,000 shares). The issue included 2,84,000 shares allocated to market maker raising ₹0.99 crore. Given the weak subscription response of 1.37 times overall, with particularly poor retail participation at 0.89 times and modest NII interest at 1.86 times, the Vijaypd Ceutical IPO share price is expected to list with flat to negative premium.

IPO उत्पन्नाचा वापर

IPO द्वारे उभारलेले फंड खालीलप्रमाणे वापरले जातील:

• Capital expenditure for construction of pharmaceutical API/intermediates and chemicals manufacturing plant: ₹10.83 crore.
• कर्जांचे रिपेमेंट/प्रीपेमेंट: ₹ 5.10 कोटी.
• सामान्य कॉर्पोरेट उद्देश: ₹ 0.74 कोटी.

बिझनेस ओव्हरव्ह्यू

Vijaypd Ceutical Limited operates with strengthened market position through long-term client relationships, comprehensive product portfolio spanning over 19,000 SKUs across pharmaceuticals and FMCG segments, streamlined supply chain management connecting with 170+ manufacturers, and experienced management team with proven execution capabilities while demonstrating exceptional financial performance with 98% revenue increase and 191% PAT rise between FY24-FY25, maintaining healthy financial metrics with 28.91% ROE and moderate debt-equity ratio of 0.68 though the boosted performance for FY25 raises sustainability questions. The company, operating since 1971, enjoys established positioning in pharmaceutical distribution segment with regulatory certifications and extensive distribution network, positioned to benefit from India's growing healthcare and FMCG sectors.